Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Editas Medicine, Inc. (EDIT) Balance Sheet

As of 2026-06-30 (10-Q), Editas Medicine, Inc. (EDIT) reported total assets of $237.4M, total liabilities of $132.1M and shareholders' equity of $105.3M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $181.8M. Long-term debt: $48.2M.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

EDITEditas Medicine, Inc.Follow EDIT — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
368.6M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
9 Nov, in 16 days
LineFY2016
Dec 16
FY2017
Dec 17
FY2018
Dec 18
FY2019
Dec 19
FY2020
Dec 20
FY2021
Dec 21
FY2022
Dec 22
FY2023
Dec 23
FY2024
Dec 24
FY2025
Dec 25
Latest
Jun 26
Trend
Cash and equivalents185.3146.6134.8238.2139.7203.5141.5123.7131.5146.6181.8
Short-term investments—182.5234.2219.0262.4296.3202.8199.5138.40.029.8
Receivables0.10.70.00.46.00.35.110.216.315.22.7
Current assets187.2332.2374.8463.8419.1507.3356.8340.8289.3163.9218.1
Total assets229.2373.3420.4508.9572.6677.5514.3499.2341.6186.5237.4
Current liabilities33.136.735.960.058.246.960.163.277.246.268.4
Long-term debt———————0.052.453.648.2
Short-term debt———————0.05.05.07.5
Total liabilities94.6165.2184.2246.4179.0123.8153.6150.1207.3159.2132.1
Shareholders' equity134.6208.1236.2262.4393.6553.6360.7349.1134.327.3105.3

USD millions · SEC XBRL

Editas Medicine, Inc. — questions

How much cash does Editas Medicine, Inc. have?
$181.8M in cash and cash equivalents as of 2026-06-30.
How much debt does Editas Medicine, Inc. have?
$48.2M of long-term debt and $7.5M due within a year as of 2026-06-30.
What are Editas Medicine, Inc.'s total assets?
$237.4M as of 2026-06-30.
What is Editas Medicine, Inc.'s shareholders' equity?
$105.3M as of 2026-06-30.

Every figure on this page comes from Editas Medicine, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.